NO3103802T3 - - Google Patents

Info

Publication number
NO3103802T3
NO3103802T3 NO15811341A NO15811341A NO3103802T3 NO 3103802 T3 NO3103802 T3 NO 3103802T3 NO 15811341 A NO15811341 A NO 15811341A NO 15811341 A NO15811341 A NO 15811341A NO 3103802 T3 NO3103802 T3 NO 3103802T3
Authority
NO
Norway
Application number
NO15811341A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO3103802T3 publication Critical patent/NO3103802T3/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO15811341A 2014-06-24 2015-06-24 NO3103802T3 (https=)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014129740 2014-06-24
JP2015024785 2015-02-10
PCT/JP2015/068218 WO2015199136A1 (ja) 2014-06-24 2015-06-24 新規ピロロピリミジン化合物又はその塩、及びこれを含有する医薬組成物、特にnae阻害作用に基づく腫瘍等の予防剤及び/又は治療剤

Publications (1)

Publication Number Publication Date
NO3103802T3 true NO3103802T3 (https=) 2018-04-07

Family

ID=54938214

Family Applications (1)

Application Number Title Priority Date Filing Date
NO15811341A NO3103802T3 (https=) 2014-06-24 2015-06-24

Country Status (21)

Country Link
US (2) US9963456B2 (https=)
EP (1) EP3103802B1 (https=)
JP (1) JP6192741B2 (https=)
KR (1) KR101947289B1 (https=)
CN (1) CN106661031B (https=)
AU (1) AU2015281155B9 (https=)
BR (1) BR112016025835B1 (https=)
CA (1) CA2946833C (https=)
DK (1) DK3103802T3 (https=)
ES (1) ES2656772T3 (https=)
HU (1) HUE037266T2 (https=)
MX (1) MX2016015015A (https=)
MY (1) MY183327A (https=)
NO (1) NO3103802T3 (https=)
PH (1) PH12016502130B1 (https=)
PL (1) PL3103802T3 (https=)
PT (1) PT3103802T (https=)
RU (1) RU2658008C2 (https=)
SG (1) SG11201608441YA (https=)
TW (1) TWI605048B (https=)
WO (1) WO2015199136A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI623316B (zh) * 2015-12-22 2018-05-11 Taiho Pharmaceutical Co Ltd Antitumor effect enhancer derived from pyrrolopyrimidine compound
WO2018085818A1 (en) * 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018085833A2 (en) * 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyl transferase 5 (prmt5)
WO2018089786A1 (en) * 2016-11-11 2018-05-17 Millennium Pharmaceuticals, Inc. Atg7 inhibitors and the uses thereof
JP7125714B2 (ja) * 2016-12-13 2022-08-25 ヤマサ醤油株式会社 抗ウイルス活性を有する2’-デオキシ-7-デアザプリンヌクレオシド誘導体
EP3740491A1 (en) * 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CN108822145B (zh) * 2018-06-11 2020-10-23 广东工业大学 一种磺酰胺类化合物及其制备方法和应用
CN108640945B (zh) * 2018-06-11 2020-10-23 广东工业大学 一种酰胺类化合物及其制备方法与应用
AU2019301697A1 (en) * 2018-07-13 2021-01-07 Il-2Rx, Inc. Compounds, compositions, methods, and uses for treating cancer and immunological disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS52458B (sr) 2005-02-04 2013-02-28 Millennium Pharmaceuticals Inc. Inhibitori e1 aktivirajućih enzima
US7989430B2 (en) 2005-12-06 2011-08-02 Regents Of The University Of Minnesota Antibacterial agents
EA024006B1 (ru) 2006-02-02 2016-08-31 Миллениум Фармасьютикалз, Инк. Ингибиторы е1 активирующих ферментов
JP2013541587A (ja) 2010-11-05 2013-11-14 ミレニアム ファーマシューティカルズ, インコーポレイテッド Nedd8活性化酵素阻害剤の投与
BR112013017184A2 (pt) 2011-01-07 2016-09-20 Leo Pharma As composto, composição farmacêutica, uso de um composto, e, método para evitar, tratar ou melhorar doenças
WO2013016906A1 (zh) * 2011-07-29 2013-02-07 深圳光启高等理工研究院 人工复合材料和人工复合材料天线
DK2657233T3 (da) * 2012-01-19 2014-09-22 Taiho Pharmaceutical Co Ltd 3,5-disubstitueret alkynylbenzenforbindelse og salt deraf

Also Published As

Publication number Publication date
CA2946833A1 (en) 2015-12-30
ES2656772T3 (es) 2018-02-28
RU2016149319A3 (https=) 2018-06-18
RU2016149319A (ru) 2018-06-18
SG11201608441YA (en) 2016-11-29
KR20170016510A (ko) 2017-02-13
PH12016502130A1 (en) 2016-12-19
US10174040B2 (en) 2019-01-08
WO2015199136A1 (ja) 2015-12-30
MY183327A (en) 2021-02-18
EP3103802A4 (en) 2017-03-08
CN106661031A (zh) 2017-05-10
BR112016025835A2 (https=) 2017-08-15
PH12016502130B1 (en) 2016-12-19
AU2015281155A1 (en) 2016-11-03
AU2015281155B9 (en) 2017-11-16
KR101947289B1 (ko) 2019-02-12
HUE037266T2 (hu) 2018-08-28
US20180162864A1 (en) 2018-06-14
PT3103802T (pt) 2017-12-11
PL3103802T3 (pl) 2018-02-28
BR112016025835B1 (pt) 2022-09-20
EP3103802A1 (en) 2016-12-14
AU2015281155B2 (en) 2017-07-13
TWI605048B (zh) 2017-11-11
JPWO2015199136A1 (ja) 2017-04-27
RU2658008C2 (ru) 2018-06-19
JP6192741B2 (ja) 2017-09-06
MX2016015015A (es) 2017-02-27
TW201625629A (zh) 2016-07-16
CN106661031B (zh) 2019-07-23
US9963456B2 (en) 2018-05-08
US20170066772A1 (en) 2017-03-09
DK3103802T3 (en) 2017-12-11
CA2946833C (en) 2019-03-05
EP3103802B1 (en) 2017-11-08

Similar Documents

Publication Publication Date Title
BR112016003450A2 (https=)
BR112016017664A2 (https=)
BR112016017872A2 (https=)
BR112016016682A2 (https=)
BR112016016834A2 (https=)
BR112016018293A2 (https=)
BR112016017913A2 (https=)
BR112016017950A2 (https=)
BR112016017265A2 (https=)
BR112016018369A2 (https=)
BR112016012568A2 (https=)
BR112016008129A2 (https=)
BR112016017526A2 (https=)
BR112016015798A2 (https=)
BR112016017660A2 (https=)
BR112016015779A2 (https=)
BR112016015768A2 (https=)
RU2016149319A3 (https=)
BR112016017739A2 (https=)
BR112016017221A2 (https=)
BR112016016798A2 (https=)
BR112014024551A2 (https=)
BR102015031789A2 (https=)
BR112016018653A2 (https=)
BR112016018337A2 (https=)